KR101521861B1 - Ａｌｋ 억제제의 사용 방법 - Google Patents

Ａｌｋ 억제제의 사용 방법 Download PDF

Info

Publication number
KR101521861B1
KR101521861B1 KR1020137023001A KR20137023001A KR101521861B1 KR 101521861 B1 KR101521861 B1 KR 101521861B1 KR 1020137023001 A KR1020137023001 A KR 1020137023001A KR 20137023001 A KR20137023001 A KR 20137023001A KR 101521861 B1 KR101521861 B1 KR 101521861B1
Authority
KR
South Korea
Prior art keywords
alk
delete delete
compound
eml4
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137023001A
Other languages
English (en)
Korean (ko)
Other versions
KR20130121174A (ko
Inventor
난신 리
제니퍼 엘. 하리스
피터 맥나마라
팡시안 선
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101521861(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20130121174A publication Critical patent/KR20130121174A/ko
Application granted granted Critical
Publication of KR101521861B1 publication Critical patent/KR101521861B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137023001A 2011-02-02 2012-02-02 Ａｌｋ 억제제의 사용 방법 Active KR101521861B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02
US61/438,878 2011-02-02
PCT/US2012/023669 WO2012106540A1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors

Publications (2)

Publication Number Publication Date
KR20130121174A KR20130121174A (ko) 2013-11-05
KR101521861B1 true KR101521861B1 (ko) 2015-05-21

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137023001A Active KR101521861B1 (ko) 2011-02-02 2012-02-02 Ａｌｋ 억제제의 사용 방법

Country Status (22)

Country Link
US (1) US8703787B2 (https=)
EP (1) EP2670401B1 (https=)
JP (1) JP5837095B2 (https=)
KR (1) KR101521861B1 (https=)
CN (1) CN103458881B (https=)
AU (1) AU2012212142B2 (https=)
BR (1) BR112013019643B1 (https=)
CA (1) CA2824092C (https=)
CY (1) CY1116662T1 (https=)
DK (1) DK2670401T3 (https=)
EA (1) EA023404B1 (https=)
ES (1) ES2543567T3 (https=)
HR (1) HRP20150946T1 (https=)
HU (1) HUE025395T2 (https=)
ME (1) ME02200B (https=)
MX (1) MX2013008791A (https=)
PL (1) PL2670401T3 (https=)
PT (1) PT2670401E (https=)
RS (1) RS54189B1 (https=)
SI (1) SI2670401T1 (https=)
SM (1) SMT201500300B (https=)
WO (1) WO2012106540A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010221B1 (pt) 2012-11-06 2022-09-13 Shanghai Fochon Pharmaceutical Co., Ltd. Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento
WO2014074580A1 (en) * 2012-11-07 2014-05-15 Novartis Ag Combination therapy
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
SG11201600055PA (en) * 2013-07-11 2016-02-26 Betta Pharmaceuticals Co Ltd Protein tyrosine kinase modulators and methods of use
JP6479812B2 (ja) * 2013-08-28 2019-03-06 ノバルティス アーゲー 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
EP3086810A2 (en) * 2013-12-23 2016-11-02 Novartis AG Pharmaceutical combinations
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CA2952787A1 (en) * 2014-06-17 2015-12-23 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
US10259816B2 (en) 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技（苏州）有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
EP3504203B1 (en) * 2016-08-29 2022-09-28 The Regents of The University of Michigan Aminopyrimidines as alk inhibitors
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
NZ585188A (en) * 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US20090236334A1 (en) 2006-07-10 2009-09-24 Rf Dynamics Ltd Food preparation
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP2311807B1 (en) * 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
US8592432B2 (en) * 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Neoplasia. Vol.13(1), pp.1-11 *
Neoplasia. Vol.13(1), pp.1-11*

Also Published As

Publication number Publication date
JP5837095B2 (ja) 2015-12-24
BR112013019643B1 (pt) 2022-04-19
CN103458881A (zh) 2013-12-18
PL2670401T3 (pl) 2015-11-30
ES2543567T3 (es) 2015-08-20
HUE025395T2 (en) 2016-02-29
CA2824092A1 (en) 2012-08-09
MX2013008791A (es) 2013-10-07
ME02200B (me) 2016-02-20
EP2670401A1 (en) 2013-12-11
SMT201500300B (it) 2016-01-08
HRP20150946T1 (hr) 2015-10-09
SI2670401T1 (sl) 2015-10-30
AU2012212142A1 (en) 2013-08-15
US20130296357A1 (en) 2013-11-07
JP2014504646A (ja) 2014-02-24
DK2670401T3 (en) 2015-09-07
EA023404B1 (ru) 2016-05-31
AU2012212142B2 (en) 2015-09-24
WO2012106540A1 (en) 2012-08-09
CA2824092C (en) 2020-06-30
EA201391114A1 (ru) 2013-12-30
CY1116662T1 (el) 2017-03-15
KR20130121174A (ko) 2013-11-05
CN103458881B (zh) 2015-08-12
BR112013019643A2 (pt) 2016-10-04
PT2670401E (pt) 2015-10-12
EP2670401B1 (en) 2015-06-10
RS54189B1 (sr) 2015-12-31
US8703787B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
KR101521861B1 (ko) Ａｌｋ 억제제의 사용 방법
CN101137382B (zh) 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂
TWI617556B (zh) 經炔基取代之喹唑啉化合物及其使用方法
JP2021501145A (ja) 血液学的障害を治療するための化合物および組成物
US12414945B2 (en) Therapeutic agent for breast cancer
CN107949387A (zh) 用谷氨酰胺酶抑制剂治疗肺癌
JP2021176819A (ja) キナゾリン化合物を有効成分とする医薬組成物
JP2019511554A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
CA3196283A1 (en) Csf1r kinase inhibitor and use thereof
JP7234418B2 (ja) Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ
CN114174269B (zh) 作用于egfr和erbb2的嘧啶类化合物
KR20210126654A (ko) 암 치료
EP3012248B1 (en) Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
TW201321383A (zh) 用於預防及治療非小細胞肺癌之包含吡嗪并三嗪衍生物的組成物
JP2024514098A (ja) ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用
Wada et al. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study
TW202140005A (zh) 用於治療發炎疾病之新穎藥物
US20250339412A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
CN103705517A (zh) Src激酶抑制剂对溶骨性病变的抑制
CN117500501A (zh) 化合物在设备用于治疗骨髓纤维化及其相关症状/体征的药物中的应用、该化合物的用途
CN117098537A (zh) 用于癌症治疗的联合疗法
HK40118235A (zh) 用於治疗或预防癌症的喹啉衍生物

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20130830

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130830

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140923

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150323

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20150429

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150514

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150515

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180427

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180427

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190429

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190429

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210428

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220427

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240430

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20250428

Start annual number: 11

End annual number: 11